Tvardi Therapeutics, Inc.
TVRD
$3.98
$0.020.51%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 28.97% | 42.75% | -0.25% | 159.74% | -127.96% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -93.58% | -83.69% | 249.47% | -12,955.32% | 5,716.84% |
| Change in Net Operating Assets | 115.46% | -78.75% | 172.48% | -51.52% | -6,554.55% |
| Cash from Operations | 23.80% | -17.63% | 36.03% | -119.04% | -85.81% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 145.72% | -- | -- | -- | -- |
| Cash from Investing | 145.72% | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -40.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -2,964.29% | -- | -- |
| Cash from Financing | -- | -100.00% | -2,200.00% | -- | -32,160.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 95.62% | -103.08% | 111.55% | 443.75% | -388.14% |